Septerna (NASDAQ:SEPN - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05, Zacks reports. The company had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.13 million.
Septerna Trading Down 5.9 %
Shares of SEPN traded down $0.36 during mid-day trading on Monday, reaching $5.74. The company had a trading volume of 202,576 shares, compared to its average volume of 460,385. The business's 50 day moving average price is $9.96. Septerna has a 1-year low of $4.17 and a 1-year high of $28.99.
Wall Street Analysts Forecast Growth
SEPN has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th. Wells Fargo & Company lowered their price objective on shares of Septerna from $14.00 to $11.00 and set an "equal weight" rating for the company in a research report on Friday.
Get Our Latest Report on SEPN
Insider Activity at Septerna
In other news, Director Alan Ezekowitz bought 41,355 shares of the stock in a transaction on Thursday, March 6th. The stock was acquired at an average price of $6.00 per share, with a total value of $248,130.00. Following the acquisition, the director now directly owns 104,101 shares in the company, valued at approximately $624,606. This trade represents a 65.91 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Gil M. Labrucherie purchased 5,000 shares of the business's stock in a transaction dated Friday, February 21st. The shares were purchased at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the purchase, the chief financial officer now directly owns 30,000 shares of the company's stock, valued at approximately $175,500. This represents a 20.00 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 74,346 shares of company stock valued at $439,670 in the last quarter.
About Septerna
(
Get Free Report)
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.
See Also
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
